Abstract
A cerebrovascular accident, or stroke, is defined as the abrupt onset of a neurological deficit, which can be due to ischemia. Cerebral ischemia is caused by a reduction in blood flow that thereby decreases cerebral metabolism. Chronic cerebral hypoperfusion leads to irreversible brain damage and plays an important role in the development of certain types of dementia. Vinpocetine, chemically known as ethyl apovincaminate, is a vinca alkaloid that exhibits cerebral blood-flow enhancing and neuroprotective effects. Nonclinical and clinical studies have suggested multiple mechanisms responsible for the beneficial neuroprotective effects of vinpocetine. As no significant side effects related to vinpocetine treatment have been reported, it is considered to be safe for long-term use. This vasoactive alkaloid is widely marketed as a supplement for vasodilation and as a nootropic for the improvement of memory. The present review focuses on studies investigating the role of vinpocetine in cerebrovascular diseases.
Similar content being viewed by others
Abbreviations
- Aβ:
-
amyloid β-peptides
- AD:
-
Alzheimer’s disease
- AEDs:
-
antiepileptic drugs
- AICVD:
-
asymptomatic ischemic cerebrovascular disorders
- ATP:
-
adenosine triphosphate
- CGI:
-
Clinical Global Impression
- cGMP:
-
cyclic guanosine monophosphate
- DOPAC:
-
3,4-dihydroxyphenylacetic acid
- DPG:
-
2,3-diphosphoglycerate
- GABA:
-
γ-aminobutyric acid
- LC:
-
locus coeruleus
- MMSQ:
-
mini-mental status questionnaire
- NMDA:
-
N-methyl-D-aspartic acid
- PET:
-
positron emission tomography
- PSNHL:
-
progressive sensorineural hearing loss
- PTZ:
-
pentylenetetrazole
- RBC:
-
red blood cell
- rCBF:
-
regional cerebral blood flow
- ROS:
-
reactive oxygen species
- RR:
-
relative risk
- SCAG:
-
Sandoz clinical assessment geriatric scale
References
Adám-Vizi V: Neuroprotective effect of sodium channel blockers in ischemia: the pathomechanism of early ischemic dysfunction (Hungarian). Orv Hetil, 2000, 141, 1279–1286.
Balestreri R, Fontana L, Astengo F: A double-blind placebo controlled evaluation of the safety and efficacy of vinpocetine in the treatment of patients with chronic vascular senile cerebral dysfunction. J Am Geriatr Soc, 1987, 35, 425–430.
Bereczki D, Fekete I: A systematic review of vinpocetine therapy in acute ischaemic stroke. Eur J Clin Pharmacol, 1999, 55, 349–352.
Bereczki D, Fekete I: Vinpocetine for acute ischemic stroke. Stroke, 2008, 39, 2404–2405.
Bonoczk P, Gulyas B, Adam-Vizi V, Nemes A, Karpati E, Kiss B, Kapas M et al.: Role of sodium channel inhibition in neuroprotection: effect of vinpocetine. Brain Res Bull, 2000, 53, 245–254.
Burtsev EM, Savkov VS, Shprakh VV, Burtsev ME: 10-years experience with using Cavinton in cerebrovascular disorders (Russian). Zh Nevropatol Psikhiatr Im S S Korsakova, 1992, 92, 56–60.
Csillik B, Mihály A, Knyihár-Csillik E: Antinociceptive effect of vinpocetine - a comprehensive survey. Ideggyogy Sz, 2010, 63, 185–192.
DeNoble VJ, Repetti SJ, Gelpke LW, Wood LM, Keim KL: Vinpocetine: nootropic effects on scopolamine-induced and hypoxia- induced retrieval deficits of a step-through passive avoidance response in rats. Pharmacol Biochem Behav, 1986, 24, 1123–1128.
Deshmukh R, Sharma V, Mehan S, Sharma N, Bedi KL: Amelioration of intracerebroventricular streptozotocin induced cognitive dysfunction and oxidative stress by vinpocetine - a PDE1 inhibitor. Eur J Pharmacol, 2009, 620, 49–56.
Dézsi L, Kis-Varga I, Nagy J, Komlódi Z, Kárpáti E: Neuroprotective effects of vinpocetine in vivo and in vitro. Apovincaminic acid derivatives as potential therapeutic tools in ischemic stroke (Hungarian). Acta Pharm Hung, 2002, 72, 84–91.
Dutov AA, Tolpyshev BA, Karpov VN, Petrov AP: Effect of Cavinton on convulsions caused by chemical substances (Russian). Farmakol Tbksikol, 1986, 49, 22–25.
Dutov AA, Gal’tvanitsa GA, Volkova VA, Sukhanova ON, Lavrishcheva TG, Petrov AP: Cavinton in the prevention of the convulsive syndrome in children after birth injury (Russian). Zh Nevropatol Psikhiatr Im S S Korsakova, 1991, 91, 21–22.
Dutov AA, Tolpyshev BA, Petrov AP, Gladun VN: Use of cavinton in epilepsy (Russian). Zh Nevropatol Psikhiatr Im S S Korsakova, 1986, 86, 850–855.
Feher G, Koltai K, Kesmarky G, Horvath B, Toth K, Komoly S, Szapary L: Effect of parenteral or oral vinpocetine on the hemorheological parameters of patients with chronic cerebrovascular diseases. Phytomedicine, 2009, 16, 111–117.
Feigin VL, Doronin BM, Popova TF, Gribatcheva EV, Tchervov DV: Vinpocetine treatment in acute ischaemic stroke: a pilot single-blind randomized clinical trial. Eur J Neurol, 2001, 8, 81–85.
Grandt R, Braun W, Schulz HU, Lührmann B, Frercks HJ: Glibenclamide steady state plasma levels during concomitant vinpocetine administration in type II diabetic patients. Arzneimittelforschung, 1989, 39, 1451–1454.
Gurkovskaia AV, Gokina NI, Buryi VA, Shuba MF: Electrophysiological analysis of the action of cavinton on the smooth muscles (Russian). Biull Eksp Biol Med, 1987, 103, 68–71.
Hadjiev D: Asymptomatic ischemic cerebrovascular disorders and neuroprotection with vinpocetine. Ideggyogy Sz, 2003, 56, 166–172.
Hadjiev D, Yancheva S: Rheoencephalographic and psychological studies with ethyl apovincaminate in cerebral vascular insufficiency. Arzneimittelforschung, 1976, 26, 1947–1950.
Hagiwara M, Endo T, Hidaka H: Effects of vinpocetine on cyclic nucleotide metabolism in vascular smooth muscle. Biochem Pharmacol, 1984, 33, 453–457.
Hayakawa M: Effect of vinpocetine on red blood cell de-formability in stroke patients. Arzneimittelforschung, 1992, 42, 425–427.
Hayakawa M: Comparative efficacy of vinpocetine, pentoxifylline and nicergoline on red blood cell deformabil-ity. Arzneimittelforschung, 1992, 42, 108–110.
Hindmarch I, Fuchs HH, Erzigkeit H: Efficacy and tolerance of vinpocetine in ambulant patients suffering from mild to moderate organic psychosyndromes. Int Clin Psychopharmacol, 1991, 6, 31–43.
Hitzenberger G, Schmid R, Braun W, Grandt R: Vinpocetine therapy does not change imipramine pharmacokinetics in man. Int J Clin Pharmacol Ther Toxicol, 1990, 28, 99–104.
Jeon KI, Xu X, Aizawa T, Lim JH, Jono H, Kwon DS, Abe J et al.: Vinpocetine inhibits NF-кB dependent inflammation via an IKK-dependent but PDE-independent mechanism. Proc Natl Acad Sci USA, 2010, 107, 9795–9800.
Kaham A, Olah M: Use of ethyl apovincaminate in oph-thalmological therapy. Arzneimittelforschung, 1976, 26, 1969–1972.
Karpati E, Szporny L: General and cerebral haemody-namic activity of ethyl apovincaminate. Arzneimittelforschung, 1976, 26, 1908–1912.
Katsuta K, Umemura K, Ueyama N, Matsuoka N: Pharmacological evidence for a correlation between hippo-campal CA1 cell damage and hyperlocomotion following global cerebral ischemia in gerbils. Eur J Pharmacol, 2003, 467, 103–109.
Kiss B, Karpati E: Mechanism of action of vinpocetine (Hungarian). Acta Pharm Hung, 1996, 66, 213–224.
Krieglstein J, Rischke R: Vinpocetine increases the neuroprotective effect of adenosine in vitro. Eur J Pharmacol, 1991, 205, 7–10.
Kuzuya F, Osawa M, Maruyama S: Effects of vinpocetine on blood viscosity and platelet aggregability. Today’s Therapy Trends, 1985, 1, 21–29.
Lakics V, Sebestyén MG, Erdö SL: Vinpocetine is a highly potent neuroprotectant against veratridine-induced cell death in primary cultures of rat cerebral cortex. Neurosci Lett, 1995, 185, 127–130.
Lamar JC, Poignet H, Beaughard M: Calcium antagonist activity of vinpocetine and vincamine in several models of cerebral ischemia. Drug Develop Res, 1988, 14, 297–304.
Lohmann A, Dingier E, Sommer W, Schaffler K, Wober W, Schmidt W: Bioavailability of vinpocetine and interference of the time of application with food intake. Arzneimittelforschung, 1992, 42, 914–917.
Lorincz C, Szasz K, Kisfaludy L: The synthesis of ethyl apovincaminate. Arzneimittelforschung, 1976, 26, 1907.
Maslarova J, Nikolov R: Antihypoxic effect of vinpocetine. Works of the Chemical Pharmaceutical Research Institute, 1999, XIX, 175–182.
Matsukawa M, Ogawa M, Nakadate K, Maeshima T, Ichitani Y, Kawai N: Serotonin and acetylcholine are crucial to maintain hippocampal synapses and memory acquisition in rats. Neurosci Lett, 1997, 230, 13–16.
McDaniel MA, Maier SF, Einstein GO: Brain-specific nutrients: a memory cure? Nutrition, 2003, 19, 957–975.
Milusheva E, Sperlagh B, Kiss B, Szporny L, Pásztor E, Papasova M, Vizi ES: Inhibitory effect of hypoxic condition on acetylcholine release is partly due to the effect of adenosine released from the tissue. Brain Res Bull, 1990, 24, 369–373.
Miskolczi P, Korma K, Polgar M, Vereczkey L: Pharmacokinetics of vinpocetine and its main metabolite apovincaminic acid before and after the chronic oral administration of vinpocetine to humans. Eur J Drug Metab Pharmacokinet, 1990, 15, 1–5.
Miyata N, Yamaura H, Tanaka M, Muramatsu M, Tsuchida K, Okuyama S, Otomo S: Effects of VA-045, a novel apovincaminic acid derivative, on isolated blood vessels: cerebroarterial selectivity. Life Sci, 1993, 52, 181–186.
Miyazaki M: The effect of cerebral vasodilator, vinpocetine, on cerebral vascular resistance evaluated by the Doppler ultrasonic technique in patients with cerebrovascular diseases. Angiology, 1995, 46, 53–58.
Nosalova V, Machova J, Babulova A: Protective action of vinpocetine against experimentally induced gastric damage in rats. Arzneimittelforschung, 1993, 43, 981–985.
Nyakas C, Felszeghy K, Szabó R, Keijser JN, Luiten PG, Szombathelyi Z, Tihanyi K: Neuroprotective effects of vinpocetine and its major metabolite cis-apovincaminic acid on NMDA-induced neurotoxicity in a rat entorhinal cortex lesion model. CNS Neurosci Ther, 2009, 15, 89–99.
Olpe HR, Steinmann MW, Jones RSG: Locus coeruleus as a target for psychogeriatric agents. Ann NY Acad Sci, 1985, 444, 399–405.
Ordögh B, Sárossy D, Klimstein G: Therapeutic action of cavinton in hearing defects of neurological origin. Ther Hung, 1978, 26, 16–19.
Orosz E, Deak Gy, Benoist Gy: Effect of ethyl apovincaminate on the cerebral circulation. Arzneimittelforschung, 1976, 26, 1951–1956.
Pálosi É, Szporny L: Effect of ethyl apovincaminate of the central nervous system. Arzneimittelforschung, 1976, 26, 1926–1929.
Pereira C, Agostinho P, Moreira PI, Duarte AI, Santos MS, Oliveira CR: Neuroprotection strategies: effect of vinpocetine in vitro oxidative stress models (Portuguese). Acta Med Port, 2003, 16, 401–406.
Pereira C, Agostinho P, Oliveira CR: Vinpocetine attenuates the metabolic dysfunction induced by amyloid beta-peptides in PC12 cells. Free Radic Res, 2000, 33, 497–506.
Polich J, Gloria R: Cognitive effects of a Ginkgo biloba/vinpocetine compound in normal adults: systematic assessment of perception, attention and memory. Hum Psychopharmacol, 2001, 16, 409–416.
Pudleiner P, Vereczkey L: Study on the absorption of vinpocetine and apovincaminic acid. Eur J Drug Metab Pharmacokinet, 1993, 18, 317–321.
Ribari O, Zelen B, Kollar B: Ethyl apovincaminate in the treatment of sensorineuronal impairment of hearing. Arzneimittelforschung, 1976, 26, 1977–1980.
Rischke R, Krieglstein J: Effects of vinpocetine on local cerebral blood flow and glucose utilization seven days after forebrain ischemia in the rat. Pharmacology, 1990, 41, 153–160.
Rischke R, Krieglstein J: Protective effect of vinpocetine against brain damage caused by ischemia. Jpn J Pharmacol, 1991, 56, 349–356.
Romodanov AP, Potapov AI: The dynamic changes in the regional volumetric cerebral blood flow and local vascular reactivity in acute craniocerebral trauma in animals with alloxan diabetes (Russian). Zh Vopr Neirokhir Im N N Burdenko, 1990, 3, 19–22.
Schmidt J: Comparative studies on the anticonvulsant effectiveness of nootropic drugs in kindled rats. Biomed Biochim Acta, 1990, 49, 413–419.
Shibuya T, Sato K: Effects of vinpocetine on experimental brain ischemia, histological study of brain monomines. IgakuNo Ayumi, 1986, 139, 217–219.
Shimizu Y, Saitoh K, Nakayama M: Agranulocytosis induced by vinpocetine. Medicine Online [serial online]. Available at: http://www.priory.com/med/vinpocetine.htm. Accessed March 08, 2008.
Sitges M, Galván E, Nekrassov V: Vinpocetine blockade of sodium channels inhibits the rise in sodium and calcium induced by 4-aminopyridine in synaptosome. Neurochem Int, 2005, 46, 533–540.
Sitges M, Guarneros A, Nekrassov V: Effects of carbamazepine, phenytoin, valproic acid, oxcarbazepine, lamotrigine, topiramate and vinpocetine on the presynaptic Ca2+ channel-mediated release of [3H]glutamate: comparison with the Na+ channel-mediated release. Neuropharmacology, 2007, 53, 854–862.
Skoromets AA, Tanashian MM, Chukanova EI, Petrova EA, Spirin NN, Nikonov AA, Peverennova IE, Levin IaI: A multicenter program on assessment of efficacy and safety of a new therapeutic scheme for patients with chronic cerebrovascular insufficiency (Russian). Zh Nevrol Psikhiatr Im S S Korsakova, 2009, 109, 44–48.
Solntseva EI, Bukanova IuV, Skrebitskii VG: Memory and potassium channels (Russian). Usp Fiziol Nauk, 2003, 34, 16–25.
Solti F, Iskum M, Czakó E: Effect of ethyl apovincaminate on the cerebral circulation. Studies in patients with obliterative cerebral arterial disease. Arzneimittelforschung, 1976, 26, 1945–1947.
Stole S: Indole derivatives as neuroprotectants. Life Sci, 1999, 65, 1943–1950.
Storm G, Oosterhuis B, Sollie FAE, Visscher HW, Sommer W, Beitinger H, Jonkman JHG: Lack of pharmacokinetic interaction between vinpocetine and oxazepam. Br J Clin Pharmcol, 1994, 38, 143–146.
Subhan Z, Hindmarch I: Psychopharmacological effects of vinpocetine in normal healthy volunteers. Eur J Clin Pharmacol, 1985, 28, 567–571.
Szakali S, Boros I, Balkay L, Emri M, Fekete I, Kerényi L, Lehel S et al.: Cerebral effects of a single dose of intravenous vinpocetine in chronic stroke patients: A PET study. J Neuroimaging, 1998, 8, 197–204.
Szapáry L, Horváth B, Alexy T, Márton Z, Késmárky G, Szóts M, Nagy F et al.: Effect of vinpocetin on the hemorheologic parameters in patients with chronic cerebrovascular disease (Hungarian). Orv Hetil, 2003, 144, 973–978.
Szatmari SZ, Whitehouse PJ: Vinpocetine for cognitive impairment and dementia. Cochrane Database Syst Rev, 2003, 1, CD003119.
Szmolenszky T, Török B: Effect of ethyl apovincaminate on cerebral, carduac and renal flow rate in dogs in the course of administration. Arzneimittelforschung, 1976, 26, 1914–1917.
Szobor A, Klein M: Ethyl apovincaminate therapy in neurovascular diseases. Arzneimittelforschung, 1976, 26, 1984–1989.
Tamaki N, Kusunoki T, Matsumoto S: The effect of vinpocetine on cerebral blood flow in patients with cerebrovascular disorders. Ther Hungar, 1985, 33, 13–21.
Tárnok K, Kiss E, Luiten PG, Nyakas C, Tihanyi K, Schlett K, Eisel UL: Effects of Vinpocetine on mitochondrial function and neuroprotection in primary cortical neurons. Neurochem Int, 2008, 53, 289–295.
Thal LJ, Salmon DP, Lasker B, Bower D, Klauber MR: The safety and lack of efficacy of vinpocetine in Alzheimer’s disease. J Am Geriatr Soc, 1989, 37, 515–520.
Tohgi H, Sasaki K, Chiba K, Nozaki Y: Effect of vinpocetine on oxygen release of hemoglobin and erythrocyte organic polyphosphate concentrations in patients with vascular dementia of the Binswanger type. Arzneimittelforschung, 1990, 40, 640–643.
Trejo F, Nekrassov V, Sitges M: Characterization of vinpocetine effects on DA and DOPAC release in striatal isolated nerve endings. Brain Res, 2001, 909, 59–67.
Truss MC, Uckert S, Stief CG, Forssmann WG, Jonas U: Cyclic nucleotide phosphodiesterase (PDE) isoenzymes in the human detrusor smooth muscle. II. Effect of various PDE inhibitors on smooth muscle tone and cyclic nucleotide levels in vitro. Urol Res, 1996, 24, 129–134.
Valikovics A: Investigation of the effect of vinpocetine on cerebral blood flow and cognitive functions (Hungarian). Ideggyogy Sz, 2007, 60, 301–310.
Vaizova OE, Vengerovskii AI, Alifirova VM: An effect of vinpocetine (cavinton) on endothelium functions in patients with chronic cerebral ischemia (Russian). Zh Nevrol Psikhiatr Im S S Korsakova, 2006, 16, 46–50.
Vereczkey L: Pharmacokinetics and metabolism of vin-camine and related compounds. Eur J Drug Metab Phar-macokinet, 1985, 10, 89–103.
World Health Organization. World Health Report 2002. Reducing Risks, Promoting Healthy Life. Geneva: WHO, 2002. (www.who.int/whr).
Yao JH, Su CY, Chu XY: Pharmacokinetics and disposition of vinpocetine in rats (Chinese). Yao Xue Xue Bao, 1994, 29, 81–85.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Patyar, S., Prakash, A., Modi, M. et al. Role of vinpocetine in cerebrovascular diseases. Pharmacol. Rep 63, 618–628 (2011). https://doi.org/10.1016/S1734-1140(11)70574-6
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1016/S1734-1140(11)70574-6